全文获取类型
收费全文 | 1438543篇 |
免费 | 115880篇 |
国内免费 | 12946篇 |
专业分类
耳鼻咽喉 | 20121篇 |
儿科学 | 46559篇 |
妇产科学 | 36340篇 |
基础医学 | 196898篇 |
口腔科学 | 36405篇 |
临床医学 | 131211篇 |
内科学 | 278123篇 |
皮肤病学 | 29916篇 |
神经病学 | 106751篇 |
特种医学 | 57333篇 |
外国民族医学 | 728篇 |
外科学 | 213026篇 |
综合类 | 62567篇 |
现状与发展 | 50篇 |
一般理论 | 387篇 |
预防医学 | 109657篇 |
眼科学 | 31532篇 |
药学 | 111998篇 |
190篇 | |
中国医学 | 15011篇 |
肿瘤学 | 82566篇 |
出版年
2021年 | 15629篇 |
2020年 | 11274篇 |
2019年 | 13713篇 |
2018年 | 18165篇 |
2017年 | 15102篇 |
2016年 | 15747篇 |
2015年 | 20082篇 |
2014年 | 26564篇 |
2013年 | 36019篇 |
2012年 | 50154篇 |
2011年 | 53239篇 |
2010年 | 34322篇 |
2009年 | 31432篇 |
2008年 | 47364篇 |
2007年 | 49517篇 |
2006年 | 49136篇 |
2005年 | 46596篇 |
2004年 | 43342篇 |
2003年 | 41867篇 |
2002年 | 40247篇 |
2001年 | 67316篇 |
2000年 | 69065篇 |
1999年 | 58356篇 |
1998年 | 16265篇 |
1997年 | 14825篇 |
1996年 | 15051篇 |
1995年 | 14227篇 |
1994年 | 13360篇 |
1993年 | 12159篇 |
1992年 | 44926篇 |
1991年 | 43767篇 |
1990年 | 42494篇 |
1989年 | 40318篇 |
1988年 | 37070篇 |
1987年 | 36412篇 |
1986年 | 33750篇 |
1985年 | 32376篇 |
1984年 | 24186篇 |
1983年 | 20306篇 |
1982年 | 11749篇 |
1979年 | 21374篇 |
1978年 | 14832篇 |
1977年 | 12550篇 |
1976年 | 11708篇 |
1975年 | 12633篇 |
1974年 | 14681篇 |
1973年 | 14139篇 |
1972年 | 12949篇 |
1971年 | 11737篇 |
1970年 | 11057篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
141.
目的 通过阿霉素(Dox)复制大鼠慢性心力衰竭(CHF)模型,观察Liguzinediol对CHF大鼠心功能的影响。方法 通过血流动力学观察Liguzinediol对Dox(腹腔注射,2 mg/kg)诱导的CHF大鼠左心室内压最大上升/下降速率(±dp/dtmax)、左心室内压(LVSP)、动脉收缩压(ASP)、动脉舒张压(ADP)和心率(HR)的变化;观察Liguzinediol对血清一氧化氮(NO)、一氧化氮合成酶(NOS)、超氧化物歧化酶(SOD)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)以及血浆中丙二醛(MDA)的影响。结果 Liguzinediol能增加LVSP、+dp/dtmax、ASP、ADP、AP、HR,降低-dp/dtmax(P<0.05~0.01);降低NO、iNOS以及MDA的浓度,同时增强了SOD的活性(P<0.05~0.01);抑制IL-6和TNF-α的生成(P<0.05~0.01)。结论 Liguzinediol可明显改善Dox诱导的CHF大鼠血流动力学指标,减少模型大鼠炎症因子的释放以及抑制氧自由基的生成。 相似文献
142.
Wei Zhang Zheng Li Feng-Qing Xu Ya-Shuo Ren Shuang-Wang Xu Tong-Sheng Wang 《Journal of Asian natural products research》2019,21(5):426-434
Two new 11-methoxyl substituted triterpenoids, named as mimengosides J (1) and K (2), along with seven known compounds, were isolated from the fruits of Buddleja lindleyana. Their structures were elucidated on the basis of spectroscopic analysis. In addition, the new ones were evaluated for protective effects against damage of SH-SY5Y cells induced by 1-methyl-4-phenylpyridinium ion (MPP+) and the results indicated that those may be one of the candidate compositions of Buddleja lindleyana for the treatment of neurodegenerative disease.
143.
144.
T.-Y. Huang Y.-J. Hsia M.-Y. Sung Y.-T. Wu P.-C. Hsu 《International journal of oral and maxillofacial surgery》2021,50(8):1100-1106
Zygomatic implant treatment is widely applied for severe maxillary atrophy to help rehabilitate the maxillary dentition. This retrospective study was performed to evaluate the actual radiographic bone–implant contact (rBIC) lengths of zygomatic implants. The records of 28 patients who underwent zygomatic implant surgery and subsequent follow-up examinations between August 2013 and September 2018 in the Department of Oral and Maxillofacial Surgery, Taipei Tzu Chi Hospital were reviewed. The surgeries were performed by a single surgeon using the same treatment protocol. All patients had a computed tomography scan at 1 year after the surgery. Using three-dimensional imaging software, an investigator measured the rBIC lengths of 66 implants and documented their clinical status. The implant survival rate was 100%. The mean rBIC length was significantly longer in male patients than in female patients (20.80 ± 5.88 mm versus 17.79 ± 6.34 mm; P = 0.028). The mean rBIC length of double zygomatic implants was significantly longer when compared to that of single implants (21.11 ± 6.23 mm versus 17.75 ± 5.85 mm; P = 0.027). This article is novel in reporting the exact rBIC lengths of zygomatic implants in a clinical setting. The results showed that zygomatic implants are a viable treatment modality for full-mouth rehabilitation. 相似文献
145.
Matrine,oxymatrine, and compound Kushen injection from the roots of Sophora flavescens: an overview of their anticancer activities
下载免费PDF全文
![点击此处可从《中国药学》网站下载免费的PDF全文](/ch/ext_images/free.gif)
In the present review, we updated current information on the chemistry, contents, and anticancer properties of matrine (MT), oxymatrine (OMT), and compound Kushen injection (CKI). The anticancer properties were focused on lung, breast, and liver cancer cells because they are most susceptible. Sources of information were from Google, Google Scholar, PubMed, PubMed Central, Science Direct, PubChem, J-Stage, Directory of Open Access Journals (DOAJ), and China National Knowledge Infrastructure (CNKI). Reference was also made on botanical websites, such as Flora of China and World Flora Online. MT and OMT are dominant quinolizidine alkaloids from the roots of Sophora flavescens (Kushen) of the family Fabaceae. Against lung, breast, and liver cancer cells, MT and OMT inhibit cell proliferation; induce cell cycle arrest, apoptosis, and autophagy; restrict angiogenesis; and inhibit cell metastasis, invasion, and migration. The processes involve various molecular targets and signaling pathways. CKI is a traditional Chinese medicine (TCM) composed of root extracts of S. flavescens and Smilax glabra (Baituling) of the family Smilacaceae. With MT and OMT as major components, CKI has been approved for the treatment of cancer in China more than 20 years ago. In recent years, systematic reviews and meta-analysis have been undertaken to evaluate the anticancer effects of CKI. When CKI is used alone and in combination with chemotherapy of western medicine, there is much to be learned concerning their interactions besides their individual and integrated efficacy. Some perspectives of MT, OMT, and CKI are discussed, and their suggestions for future research are provided. 相似文献
146.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
147.
148.
149.
150.
In both adults and children with diabetes, technologies such as continuous subcutaneous insulin infusion using insulin pumps and continuous glucose monitoring can help improve diabetes control, reduce hypoglycaemia and improve quality of life. Access to these technologies in the UK is very variable. Some technologies are recommended by the National Institute for Health and Care Excellence, while others have not been appraised, and new technologies are emerging all the time. Additionally, different guidelines for adults and children further complicate access to diabetes technology in the transition from paediatric to adult care. Against this background, Diabetes UK and NHS England have brought together a multidisciplinary group of experts, including clinicians and people with diabetes, to develop this consensus guideline, combining the different technologies into a common pathway to aid clinical and policy decision‐making. We created a pathway that supports the incremental addition of technology as monotherapy and then dual therapy in the same way that we incrementally add in therapeutic agents to support people with Type 2 diabetes to achieve their personalized glycaemic targets. The pathway emphasizes the importance of structured education, specialist support and appropriate access to psychological therapies, as essential pillars for optimized use of diabetes‐related technology, and recommends the re‐evaluation of its use when the individual is unable either to use the technology appropriately or to achieve the intended outcomes. This pathway is endorsed by UK‐wide clinical and patient associations and we recommend that providers and commissioners use it to ensure the right individual with diabetes has access to the right technology in a timely way to help achieve better outcomes. 相似文献